Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications
November 09, 2020 01:00 ET
|
Angion Biomedica Corp
Vifor Pharma acquires a worldwide license, excluding Greater China, to late-stage product ANG-3777 ANG-3777 is a first-in-class small-molecule hepatocyte growth factor (HGF) mimetic,...
Angion to Present Multiple Posters at Kidney Week 2020
October 09, 2020 10:33 ET
|
Angion Biomedica Corp
SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion Enrolls First Patients in Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia
August 04, 2020 00:01 ET
|
Angion Biomedica Corp
SAN FRANCISCO and COVINGTON, Ky., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and...
Angion Initiates Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia
July 08, 2020 00:01 ET
|
Angion Biomedica Corp
SAN FRANCISCO, July 08, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion Announces Key Addition to Management Team and Appointments to Board of Directors
June 04, 2020 00:01 ET
|
Angion Biomedica Corp
Appoints Jennifer J. Rhodes as Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary - - - Strengthens the Board of Directors with the addition of industry...
Angion to Present Results from Multiple Preclinical and Health Economic Studies at the American Transplant Congress Virtual Meeting
May 29, 2020 10:22 ET
|
Angion Biomedica Corp
SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small...
Angion Announces Publication of ANG-3777 Phase 2 Results in the Scientific Journal Transplantation
May 05, 2020 00:01 ET
|
Angion Biomedica Corp
SAN FRANCISCO, May 05, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion Initiates Dosing in Phase 1 Clinical Trial Evaluating ANG-3070, a Dual-Kinase Inhibitor for the Treatment of Fibrotic Diseases
December 18, 2019 10:00 ET
|
Angion Biomedica Corp
SAN FRANCISCO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a clinical stage biopharmaceutical company developing first-in-class therapies to treat acute kidney injury and...
Angion Presents Data on the Impact and Burden of Delayed Graft Function at the American Society of Nephrology Kidney Week 2019
November 11, 2019 10:00 ET
|
Angion Biomedica Corp
SAN FRANCISCO, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a clinical stage biopharmaceutical company developing a first-in-class therapy to treat acute kidney injury,...
Angion Presents Positive Long-term Data from Phase 2 Clinical Trial of ANG-3777 in Delayed Graft Function at the American Society of Nephrology Kidney Week 2019
November 07, 2019 12:15 ET
|
Angion Biomedica Corp
ANG-3777 shows improved short- and long-term graft function with a positive safety profile in a Phase 2 study New data support company’s ongoing Phase 3 study UNIONDALE, N.Y., Nov. 07, 2019 ...